Globus Medical, Inc. (NYSE:GMED) is one of the Best 52-Week Low Stocks to Buy According to Analysts. On July 3, Piper Sandler analyst Matthew O’Brien maintained a Buy rating on Globus Medical, Inc. (NYSE:GMED) with a price target of $80.
The firm maintained a bullish sentiment despite the company posting a weak fiscal first quarter of 2025. Globus Medical, Inc. posted a revenue of $598.12, slightly down by 1.41% year-over-year, and below consensus by $27.78 million. The EPS of $0.68 also missed the target by -$0.06.
A medical professional conducting a minimally invasive procedure using a cutting-edge medical device.
On the bright side, the US sales were steady, rising by 0.2%. Management noted that the main reason for weaker sales was fewer enabling technology deals and some supply chain issues. The timing of orders from international distributors also played a part. Despite these challenges, the company’s US spine business remained strong and offset some of the decline. Management has reaffirmed the full-year guidance and is expecting revenue between $2.8 billion and $2.9 billion.
Globus Medical, Inc. is a medical device company specializing in developing and commercializing solutions for musculoskeletal disorders.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
This article is originally published at Insider Monkey.
